Senseonics Unveils Strategy to Accelerate Growth With One-Year CGM System

Senseonics Holdings Inc. has highlighted its commercial strategy and product developments in a recent investor presentation. The company is focused on growth within the global continuous glucose monitoring (CGM) market, which is projected to reach $13.5 billion in 2025. Senseonics is addressing common patient concerns such as sensor longevity, accuracy, and skin irritation, and is promoting its Eversense 365 system, described as the world’s first and only one-year CGM system. The company’s roadmap emphasizes increasing awareness, expanding market access, and improving patient retention. Strategies include targeted marketing, optimizing its inserter network, expanding commercial capacity, and enhancing user experience. Senseonics aims to unlock operational efficiencies and drive revenue growth in an underpenetrated market. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here